公开(公告)号：WO2013185082A3

公开(公告)日：2014-04-03

申请号：PCT/US2013044797

申请日：2013-06-07

Applicant: BIOGEN IDEC INC ,  SUNESIS PHARMACEUTICALS INC

Inventor： HOPKINS BRIAN T ,  CAI XIONGWEI ,  CHAN TIMOTHY R ,  CONLON PATRICK ,  HUMORA MICHAEL ,  JENKINS TRACY J ,  MACPHEE J MICHAEL ,  SHI XIANGLIN ,  MILLER ROSS A ,  THOMPSON ANDREW

IPC: A01N43/40 ,  A61K31/435 ,  A61K31/445

CPC classification number: C07D401/14 ,  C07B2200/13 ,  C07D207/16 ,  C07D207/28 ,  C07D211/56 ,  C07D401/04

Abstract: The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.

Abstract translation: 本发明提供了一种化合物，固体形式及其组合物，其可用作Bruton酪氨酸激酶的抑制剂，并且其表现出对其的期望特性。 本发明还提供了制备所提供的化合物和固体形式的方法。

公开(公告)号：WO2012058645A8

公开(公告)日：2012-06-28

申请号：PCT/US2011058472

申请日：2011-10-28

Applicant: BIOGEN IDEC INC ,  SUNESIS PHARMACEUTICALS INC ,  HOPKINS BRIAN T ,  SCOTT DANIEL ,  CONLON PATRICK ,  JENKINS TRACY J ,  POWELL NOEL ,  GUAN BING ,  CUERVO JULIO H ,  WANG DEPING ,  TAVERAS ART

Inventor： HOPKINS BRIAN T ,  SCOTT DANIEL ,  CONLON PATRICK ,  JENKINS TRACY J ,  POWELL NOEL ,  GUAN BING ,  CUERVO JULIO H ,  WANG DEPING ,  TAVERAS ART

IPC: C07D211/60

CPC classification number: A61K31/553 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D403/04 ,  C07D413/12 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.

Abstract translation: 本发明提供了可用作Tec家族激酶抑制剂的化合物，其组合物及其使用方法。 在某些实施方案中，本发明提供包含所提供化合物的药物制剂。 在某些实施方案中，本发明提供降低Tec激酶家族成员的酶活性的方法。 在一些实施方案中，这些方法包括使Tec激酶家族成员与有效量的Tec激酶家族成员抑制剂接触。 在某些实施方案中，本发明提供在有需要的受试者中治疗对Tec激酶家族抑制有反应的病症的方法。

公开(公告)号：WO2009006404A2

公开(公告)日：2009-01-08

申请号：PCT/US2008068789

申请日：2008-06-30

Applicant: SUNESIS PHARMACEUTICALS INC ,  COSSROW JENNIFER ,  GUAN BING ,  ISHCHENKO ALEXEY ,  JONES JOHN HOWARD ,  KUMARAVEL GNANASAMBANDAM ,  LUGOVSKOY ALEXEY ,  PENG HAIRUO ,  POWELL NOEL ,  RAIMUNDO BRIAN ,  TANAKA HIROKO ,  VESSELS JEFFREY ,  WYNN THOMAS ,  XIN ZHILI

Inventor： COSSROW JENNIFER ,  GUAN BING ,  ISHCHENKO ALEXEY ,  JONES JOHN HOWARD ,  KUMARAVEL GNANASAMBANDAM ,  LUGOVSKOY ALEXEY ,  PENG HAIRUO ,  POWELL NOEL ,  RAIMUNDO BRIAN ,  TANAKA HIROKO ,  VESSELS JEFFREY ,  WYNN THOMAS ,  XIN ZHILI

IPC: C07D413/12 ,  A61K31/505 ,  A61P35/00 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

CPC classification number: C07D417/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Abstract translation: 本发明提供了可用作Raf蛋白激酶抑制剂的化合物。 本发明还提供了其组合物，以及Raf介导的疾病的治疗方法。

公开(公告)号：WO2008100622A2

公开(公告)日：2008-08-21

申请号：PCT/US2008002112

申请日：2008-02-15

Applicant: SUNESIS PHARMACEUTICALS INC ,  ALLEN DARIN ,  CHOONG INGRID ,  LEW WILLARD

Inventor： ALLEN DARIN ,  CHOONG INGRID ,  LEW WILLARD

IPC: C07D471/04 ,  A61K31/437 ,  A61P17/06 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00

CPC classification number: C07D471/04

Abstract: Biaryl-substituted tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.

Abstract translation: 描述了联芳基取代的四氢 - 吡唑并吡啶化合物，其可用作组织蛋白酶S调节剂。 这些化合物可用于治疗由组织蛋白酶S活性介导的疾病状态，病症和病症的药物组合物和方法，例如银屑病，疼痛，多发性硬化，动脉粥样硬化和类风湿性关节炎。

公开(公告)号：WO2008016678A2

公开(公告)日：2008-02-07

申请号：PCT/US2007/017248

申请日：2007-08-01

Applicant: SUNESIS PHARMACEUTICALS, INC. ,  JACOBS, Jeffrey, W.

Inventor： JACOBS, Jeffrey, W.

IPC: A61K9/08

CPC classification number: A61K31/4375

Abstract: Provided herein are light protective pharmaceutical packages for enantiomerically pme (+)-l,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylarnino)-l-pyrrolidinyl]-4-oxo-l-(2- thiazolyl)-l,8-naphthyridine-3-carboxylic acid. In certain embodiments, the pharmaceutical packages comprise a glass vial containing SNS-595 drug product within a secondary container.

Abstract translation: 本文提供了对映异构体（+） - 1,4-二氢-7 - [（3S，4S）-3-甲氧基-4-（甲基氨基）-1-吡咯烷基] -4-氧代-1- （2-噻唑基）-1,8-萘啶-3-羧酸。 在某些实施方案中，药物包装包含在次级容器内含有SNS-595药物产品的玻璃小瓶。

公开(公告)号：WO2007146335A3

公开(公告)日：2007-12-21

申请号：PCT/US2007/013873

申请日：2007-06-12

Applicant: SUNESIS PHARMACEUTICALS, INC. ,  ADELMAN, Daniel, C. ,  EVANCHIK, Marc, J. ,  SUDHAKAR, Anantha ,  JACOBS, Jeffrey, William ,  SILVERMAN, Jeffrey, A.

Inventor： ADELMAN, Daniel, C. ,  EVANCHIK, Marc, J. ,  SUDHAKAR, Anantha ,  JACOBS, Jeffrey, William ,  SILVERMAN, Jeffrey, A.

IPC: A61K31/4745 ,  A61P35/00

Abstract: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.

公开(公告)号：WO2007079445A3

公开(公告)日：2007-07-12

申请号：PCT/US2007/000131

申请日：2007-01-03

Applicant: SUNESIS PHARMACEUTICALS, INC. ,  ROMANOWSKI, Michael, J. ,  RANDAL, L., Michael

Inventor： ROMANOWSKI, Michael, J. ,  RANDAL, L., Michael

IPC: G01N33/53

Abstract: The present invention is directed to Aurora constructs that are useful for structural and functional studies of Aurora. Specifically, engineered Aurora enzymes are provided, along with polynucleotides encoding said enzymes, vectors comprising said polynucleotides, and host cells comprising the vectors. In addition, a process of using the engineered Aurora enzymes to identify Aurora modulators is provided.

公开(公告)号：WO2007011810A1

公开(公告)日：2007-01-25

申请号：PCT/US2006/027544

申请日：2006-07-14

Applicant: MERCK & CO., INC. ,  SUNESIS PHARMACEUTICALS, INC. ,  COBURN, Craig, A. ,  EGBERTSON, Melissa, S. ,  GRAHAM, Samuel, L. ,  MCGAUGHEY, Georgia, B. ,  STAUFFER, Shaun, R. ,  YANG, Wenjin ,  LU, Wanli ,  FAHR, Bruce

Inventor： COBURN, Craig, A. ,  EGBERTSON, Melissa, S. ,  GRAHAM, Samuel, L. ,  MCGAUGHEY, Georgia, B. ,  STAUFFER, Shaun, R. ,  YANG, Wenjin ,  LU, Wanli ,  FAHR, Bruce

IPC: C07D471/10 ,  A61K31/438 ,  A61P25/28

CPC classification number: C07D471/10

Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of diseases in which the beta-secretase enzyme is involved.

Abstract translation: 本发明涉及式（I）的螺哌啶化合物及其互变异构体，其是β-分泌酶的抑制剂，并且其可用于治疗涉及β-分泌酶的疾病，例如阿尔茨海默氏病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在治疗涉及β-分泌酶的疾病中的用途。

公开(公告)号：WO2004056962A3

公开(公告)日：2006-02-16

申请号：PCT/US0338314

申请日：2003-12-02

Applicant: SUNESIS PHARMACEUTICALS INC

Inventor： BALLINGER MARCUS

IPC: C12N9/64 ,  C12N9/00

CPC classification number: C12N9/6421

Abstract: The present invention is directed to engineered polypeptides having BACE activity. In certain embodiments, the polypeptides also comprise an engineered cleavage site. Also provided are polypeptides comprising a prodomain, an engineered cleavage site, and a protease domain; the polypeptides are properly folded and are cleaved at the engineered cleavage site in vitro, producing homogeneous preparations of purified protease having BACE activity. The invention further pertains to nucleic acids, expression vectors, and host cells comprising the expression vectors for making the engineered polypeptides.

公开(公告)号：WO2005089757A1

公开(公告)日：2005-09-29

申请号：PCT/US2005/008346

申请日：2005-03-14

Applicant: SUNESIS PHARMACEUTICALS, INC. ,  ADELMAN, Daniel, C. ,  SILVERMAN, Jeffrey, A.

Inventor： ADELMAN, Daniel, C. ,  SILVERMAN, Jeffrey, A.

IPC: A61K31/44

CPC classification number: A61K31/4375 ,  A61K9/0019 ,  A61K31/282 ,  A61K31/337 ,  A61K31/395 ,  A61K31/407 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/555 ,  A61K31/585 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/15 ,  A61K38/1816 ,  A61K41/00 ,  A61K45/06 ,  A61K47/12 ,  C07D471/04 ,  F24S10/70 ,  F24S50/40 ,  F24S60/30 ,  F24S80/60 ,  H01L31/0547 ,  H02S40/38 ,  Y02E10/40 ,  Y02E10/52 ,  A61K2300/00

Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same. Figure 1 depicts the plasma concentrations of SNS-595 over time among the various patient cohorts.

Abstract translation: 本发明涉及SNS-595及使用其的癌症治疗方法。 图1描述了各种患者队列中SNS-595随时间的血浆浓度。